Elevated levels of MMP-9 in untreated patients with stage i essential hypertension

Clinical and Experimental Hypertension

Volumn 34, Issue 8, 2012, Pages 561-566

  Gkaliagkousi, Eugenia ^a   Doumas, Michail ^a   Gavriilaki, Eleni ^a   Triantafyllou, Areti ^a   Vogiatzis, Konstantinos ^a   Anyfanti, Panagiota ^a   Petidis, Konstantinos ^a   Douma, Stella ^a  

^a Aristotle University Medical School   (Greece)

Author keywords

Essential hypertension; Metalloproteinases; MMP 2; MMP 9; TIMP 1

Indexed keywords

GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; GLYCEMIC CONTROL; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEASE INHIBITORS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870443779     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.681726     Document Type: Article

References (31)

1. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3):251-262.
2. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110(5):625-632.
3. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysminfiltrating macrophages. J Clin Invest 1995; 96(1):318-326.
4. Yamashita K, Hayakawa T. Assaying growth factor activity of tissue inhibitors of metalloproteinases. Methods Mol Biol 2001; 151:533-537.
5. Muhs BE, Patel S, Yee H, Marcus S, Shamamian P. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res 2003; 109 (2):110-117.
6. Galis ZS, MuszynskiM, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748:501-507.
7. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92(2):402-406.
8. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6):2493-2503.
9. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107(12):1579-1585.
10. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4):598-603.
11. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109(23):2850-2856.
12. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97(2):175-180.
13. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31(9):413-418.
14. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96(3): 339-345.
15. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30(10):959-963.
16. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17(9):764-769.
17. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75(1): 43-47.
18. Zhou S, Feely J, Spiers JP, Mahmud A. Matrix metalloproteinase- 9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 2007; 21(11): 861-867.
19. Yasmin SW, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25(2):372.
20. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12):1462-1536.
21. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19(2):149-154.
22. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27(21):2588-2605.
23. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. JAmCollCardiol 1998; 32(2):368-372.
24. Vlachopoulos C, Aznaouridis K, Dima I, et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol 2007; 122(3): 232-238.
25. Odenbach J, Wang X, Cooper S, et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011; 57(1):123-130.
26. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98(6):535-540.
27. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40(2):136-141.
28. SzmigielskiC, RaczkowskaM, StyczynskiG, Pruszczyk P, Gaciong Z.Metabolismof collagen is altered in hypertensives with increased intima media thickness. Blood Press 2006; 15(3):157-163.
29. Papadopoulos DP, Thomopoulos C, Perrea D, et al. Changes of metalloproteinases profile in patients with masked hypertension. Angiology 2009; 60(6):757-762.
30. Papadopoulos DP, Makris TK, Krespi PG, et al. Changes in metalloproteinases in healthy normotensive patients with highnormal blood pressure. Eur Cytokine Netw 2005; 16(3): 211-214.
31. Marchesi C, Dentali F, Nicolini E, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2011; 30:3-16.